Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
argenx NV ADR is a biotechnology business based in the US. argenx NV ADR shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx NV ADR employs 843 staff and has a trailing 12-month revenue of around $441 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $372.58 |
|---|---|
| 52-week range | $267.35 - $407.93 |
| 50-day moving average | $367.00 |
| 200-day moving average | $370.52 |
| Wall St. target price | $452.95 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-13.05 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $372.58 from 2023-03-31
| 1 week (2023-03-24) | 3.35% |
|---|---|
| 1 month (2023-03-02) | 7.98% |
| 3 months (2022-12-30) | -1.65% |
| 6 months (2022-09-30) | 5.53% |
| 1 year (2022-04-01) | 14.50% |
|---|---|
| 2 years (2021-04-01) | 31.95% |
| 3 years (2020-04-02) | 179.48% |
| 5 years (2018-03-29) | 363.18% |
| Revenue TTM | $441 million |
|---|---|
| Gross profit TTM | $-251,786,000 |
| Return on assets TTM | -15.12% |
| Return on equity TTM | -26.54% |
| Profit margin | -160.9% |
| Book value | $50.79 |
| Market capitalisation | $20.6 billion |
TTM: trailing 12 months
We're not expecting argenx NV ADR to pay a dividend over the next 12 months.
Over the last 12 months, argenx NV ADR's shares have ranged in value from as little as $267.345 up to $407.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx NV ADR's is 0.4762. This would suggest that argenx NV ADR's shares are less volatile than average (for this exchange).
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S. À. R.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.